Abstract
Shapeshifters, in common mythology, are entities that can undergo multiple physical transformations. As our understanding of G protein-coupled receptors (GPCRs) has accelerated and been refined over the last two decades, we now understand that GPCRs are not static proteins, but rather dynamic structures capable of moving from one posture to the next, and adopting unique functional characteristics at each transition. This model of GPCR dynamics underlies our current understanding of biased agonism—how different ligands to the same receptor can generate different intracellular signals—and constitutive receptor activity, or the level of unbound basal receptor signaling that can be attenuated by inverse agonists. From information derived from related class B receptors, we have recently modeled the structure and molecular dynamics of the full-length pituitary adenylate cyclase activating polypeptide (PACAP, Adcyap1)—selective PAC1 receptor (PAC1R, Adcyap1r1). The class B receptors are different from the class A GPCRs in part from the presence of a large extracellular domain (ECD); the transitions of the ECD along with the dynamics of the transmembrane domains (TMD or 7TM) of the PAC1R describes a series of open- and closed-state conformations that appear to identify the mechanisms for receptor activation. The PAC1R shapeshifts also have the ability of delineating the mechanisms and the design of reagents that may direct biased agonism (or antagonism) for potential therapeutics.
Similar content being viewed by others
References
Adan RA, Kas MJ (2003) Inverse agonism gains weight. Trends Pharmacol Sci 24:315–321
Alexander RW, Eargle J, Luthey-Schulten Z (2010) Experimental and computational determination of tRNA dynamics. FEBS Lett 584:376–386
Arimura A, Somogyvári-Vigh A, Miyata A, Mizuno K, Coy DH, Kitada C (1991) Tissue distribution of PACAP as determined by RIA: highly abundant in the rat brain and testes. Endocrinology 129:2787–2789
Black Pyrkosz A, Eargle J, Sethi A, Luthey-Schulten Z (2010) Exit strategies for charged tRNA from GluRS. J Mol Biol 397:1350–1371
Blechman J, Levkowitz G (2013) Alternative splicing of the pituitary adenylate cyclase-activating polypeptide receptor PAC1: mechanisms of fine tuning of brain activity. Front Endocrinol 4:55
Bowman GR, Huang X, Pande VS (2009) Using generalized ensemble simulations and Markov state models to identify conformational states. Methods 49:197–201
Braas KM, May V (1999) Pituitary adenylate cyclase-activating polypeptides directly stimulate sympathetic neuron neuropeptide Y release through PAC(1) receptor isoform activation of specific intracellular signaling pathways. J Biol Chem 274(39):27702–27710
Culhane KJ, Liu Y, Cai Y, Yan EC (2015) Transmembrane signal transduction by peptide hormones via family B G protein-coupled receptors. Front Pharmacol 6:264
de Graaf C, Song G, Cao C, Zhao Q, Wang MW, Wu B, Stevens RC (2017) Extending the structural view of class B GPCRs. Trends Biochem Sci 42:946–960
Edvinsson L, Tajti J, Szalárdy L, Vécsei L (2018) PACAP and its role in primary headaches. J Headache Pain 19(1):21
Geppetti P, Veldhuis NA, Lieu T, Bunnett NW (2015) G protein-coupled receptors: dynamic machines for signaling pain and itch. Neuron 88:635–649
Hammack SE, May V (2015) Pituitary adenylate cyclase activating polypeptide in stress-related disorders: data convergence from animal and human studies. Biol Psychiatry 78:167–177
Hammack SE, Cheung J, Rhodes KM, Schutz KC, Falls WA, Braas KM, May V (2009) Chronic stress increases pituitary adenylate cyclase-activating peptide (PACAP) and brain-derived neurotrophic factor (BDNF) mRNA expression in the bed nucleus of the stria terminalis (BNST): roles for PACAP in anxiety-like behavior. Psychoneuroendocrinology 34:833–843
Harmar AJ, Fahrenkrug J, Gozes I, Laburthe M, May V, Pisegna JR, Vaudry D, Vaudry H, Waschek JA, Said SI (2012) Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol 166:4–17
Hollenstein K, de Graaf C, Bortolato A, Wang MW, Marshall FH, Stevens RC (2014) Insights into the structure of class B GPCRs. Trends Pharmacol Sci 35:12–22
Hollenstein K, Kean J, Bortolato A, Cheng RKY, Doré AS, Jazayeri A, Cooke RM, Weir M, Marshall FH (2013) Structure of class B GPCR corticotropin-releasing factor receptor 1. Nature 438:438–443
Jazayeri A, Doré AS, Lamb D, Krishnamurthy H, Southall SM, Baig AH, Bortolato A, Koglin M, Robertson NJ, Errey JC, Andrews SP, Teobald I, Brown AJH, Cooke RM, Weir M, Marshall FH (2016) Extra-helical binding site of a glucagon receptor antagonist. Nature 533:274–277
Jazayeri A, Rappas M, Brown AJH, Kean J, Errey JC, Robertson NJ, Fiez-Vandal C, Andrews SP, Congreve M, Bortolato A, Mason JS, Baig AH, Teobald I, Doré AS, Weir M, Cooke RM, Marshall FH (2017) Crystal structure of the GLP-1 receptor bound to a peptide agonist. Nature 546:254–258
Katritch V, Cherezov V, Stevens RC (2013) Structure-function of the G protein-coupled receptor superfamily. Annu Rev Pharmacol Toxicol 53:531–556
Kenakin T, Miller LJ (2010) Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 62:265–304
Kimura C, Ohkubo S, Ogi K, Hosoya M, Itoh Y, Onda H, Miyata A, Jiang L, Dahl RR, Stibbs HH et al (1990) A novel peptide which stimulates adenylate cyclase: molecular cloning and characterization of the ovine and human cDNAs. Biochem Biophys Res Commun 166:81–89
Latorraca NR, Venkatakrishnan AJ, Dror RO (2017) GPCR dynamics: structures in motion. Chem Rev 117(1):139–155
Li J, Jonsson AL, Beuming T, Shelley JC, Voth GA (2013) Ligand-dependent activation and deactivation of the human adenosine a(2A) receptor. J Am Chem Soc 135:8749–8759
Liang YL, Khoshouei M, Radjainia M, Zhang Y, Glukhova A, Tarrasch J, Thal DM, Furness SGB, Christopoulos G, Coudrat T, Danev R, Baumeister W, Miller LJ, Christopoulos A, Kobilka BK, Wootten D, Skiniotis G, Sexton PM (2017) Phase-plate cryo-EM structure of a class B GPCR-G-protein complex. Nature 546:118–123
Liao C, Zhao X, Brewer M, May V, Li J (2017) Conformational transitions of the pituitary adenylate cyclase-activating polypeptide receptor, a human class B GPCR. Sci Rep 7:5427
Luttrell LM, Maudsley S, Bohn LM (2015) Fulfilling the promise of "biased" G protein-coupled receptor agonism. Mol Pharmacol 88:579–588
Manglik A, Lin H, Aryal DK, McCorvy JD, Dengler D, Corder G, Levit A, Kling RC, Bernat V, Hübner H, Huang XP, Sassano MF, Giguère PM, Löber S, Duan D, Scherrer G, Kobilka BK, Gmeiner P, Roth BL, Shoichet BK (2016) Structure-based discovery of opioid analgesics with reduced side effects. Nature 537:185–190
May V, Braas KM (1995) Pituitary adenylate cyclase-activating polypeptide (PACAP) regulation of sympathetic neuron neuropeptide Y and catecholamine expression. J Neurochem 65:978–987
Miles OW, Thrailkill EA, Linden AK, May V, Bouton ME, Hammack SE (2018) Pituitary adenylate cyclase-activating peptide in the bed nucleus of the stria terminalis mediates stress-induced reinstatement of cocaine seeking in rats. Neuropsychopharmacology 43:978–986
Missig G, Roman CW, Vizzard MA, Braas KM, Hammack SE, May V (2014) Parabrachial nucleus (PBn) pituitary adenylate cyclase activating polypeptide (PACAP) signaling in the amygdala: implication for the sensory and behavioral effects of pain. Neuropharmacology 86:38–48
Missig G, Mei M, Vizzard MA, Braas KM, Waschek JA, Ressler KJ, Hammack SE, May V (2016) Parabrachial PACAP activation of amygdala endosomal ERK signaling regulates the emotional component of pain. Biol Psychiatry (in press):http://www.biologicalpsychiatryjournal.com/article/S0006-3223(0016)32725-32721/fulltext
Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, Jiang L, Culler MD, Coy DH (1989) Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 164:567–574
Moro O, Lerner EA (1997) Maxadilan, the vasodilator from sand flies is a specific pituitary adenylate cyclase activating polypeptide type I receptor agonist. J Biol Chem 272:966–970
Pándy-Szekeres G, Munk C, Tsonkov TM, Mordalski S, Harpsøe K, Hauser AS, Bojarski AJ, Gloriam DE (2018) GPCRdb in 2018: adding GPCR structure models and ligands. Nucleic Acids Res 46:D440–D446
Pantaloni C, Brabet P, Bilanges B, Dumuis A, Houssami S, Spengler D, Bockaert J, Journot L (1996) Alternative splicing in the N-terminal extracellular domain of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor modulates receptor selectivity and relative potencies of PACAP-27 and PACAP-38 in phospholipase C activation. J Biol Chem 271:22146–22151
Park PS (2012) Ensemble of G protein-coupled receptor active states. Curr Med Chem 19:1146–1154
Pisegna JR, Wank SA (1996) Cloning and characterization of signal transduction of four splice variants of the human pituitary adenylate cyclase activating polypeptide receptor. J Biol Chem 271:17267–17274
Prinz JH, Wu H, Sarich M, Keller B, Senne M, Held M, Chodera JD, Schütte C, Noé F (2011) Markov models of molecular kinetics: generation and validation. J Chem Phys 134:174105
Pupo AS, Duarte DA, Lima V, Teixeira LB, Parreiras-E-Silva LT, Costa-Neto CM (2016) Recent updates on GPCR biased agonism. Pharmacol Res 112:49–57
Ressler KJ, Mercer KB, Bradley B, Jovanovic T, Mahan A, Kerley K, Norrholm SD, Kilaru V, Smith AK, Myers AJ, Ramirez M, Engel A, Hammack SE, Toufexis D, Braas KM, Binder EB, May V (2011) Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor. Nature 470:492–497
Roman CW, Lezak KR, Hartsock MJ, Falls WA, Braas KM, Howard AB, Hammack SE, May V (2014) PAC1 receptor antagonism in the bed nucleus of the stria terminalis (BNST) attenuates the endocrine and behavioral consequences of chronic stress. Psychoneuroendocrinology 47:151-165
Rosenbaum DM, Rasmussen SG, Kobilka BK (2009) The structure and function of G-protein-coupled receptors. Nature 459:356–363
Sethi A, Eargle J, Black AA, Luthey-Schulten Z (2009) Dynamical networks in tRNA:protein complexes. Proc Natl Acad Sci U S A 106:6620–6625
Sherwood NM, Krueckl SL, McRory JE (2000) The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocr Rev 21:619–670
Siu FY, He M, de Graaf C, Han GW, Yang D, Zhang Z, Zhou C, Xu Q, Wacker D, Joseph JS, Liu W, Lau J, Cherezov V, Katritch V, Wang MW, Stevens RC (2013) Structure of the human glucagon class B G-protein-coupled receptor. Nature 499(7459):444–449
Song G et al (2017) Human GLP-1 receptor transmembrane domain structure in complex with allosteric modulators. Nature 546:312–315
Spengler D, Waeber C, Pantaloni C, Holsboer F, Bockaert J, Seeburg PH, Journot L (1993) Differential signal transduction by five splice variants of the PACAP receptor. Nature 365:170–175
Stroth N, Eiden LE (2010) Stress hormone synthesis in mouse hypothalamus and adrenal gland triggered by restraint is dependent on pituitary adenylate cyclase-activating polypeptide signaling. Neuroscience 165:1025–1030
Vaudry D, Falluel-Morel A, Bourgault S, Basille M, Burel D, Wurtz O et al (2009) Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev 61:283–357
Wacker D, Stevens RC, Roth BL (2017) How ligands illuminate GPCR molecular pharmacology. Cell 170:414–427
Weinan E, Vanden-Eijnden E (2006) Towards a theory of transition paths. J Stat Phys 123:503–523
Wootten D, Miller LJ, Koole C, Christopoulos A, Sexton PM (2017) Allostery and biased agonism at class B G protein-coupled receptors. Chem Rev 117:111–138
Yang L, Yang D, de Graaf C, Moeller A, West GM, Dharmarajan V, Wang C, Siu FY, Song G, Reedtz-Runge S, Pascal BD, Wu B, Potter CS, Zhou H, Griffin PR, Carragher B, Yang H, Wang MW, Stevens RC, Jiang H (2015) Conformational states of the full-length glucagon receptor. Nat Commun 6:7859
Yuan S, Hu Z, Filipek S, Vogel H (2015) W246(6.48) opens a gate for a continuous intrinsic water pathway during activation of the adenosine A2A receptor. Angew Chem Int Ed Engl 54:556–559
Zhang D, Zhao Q, Wu B (2015) Structural studies of G protein-coupled receptors. Mol Cells 38:836–842
Zhang H et al (2018) Structure of the glucagon receptor in complex with a glucagon analogue. Nature 553:106–110
Zhang H et al (2017a) Structure of the full-length glucagon class B G-protein-coupled receptor. Nature 546:259–264
Zhang Y, Sun B, Feng D, Hu H, Chu M, Qu Q, Tarrasch JT, Li S, Sun Kobilka T, Kobilka BK, Skiniotis G (2017b) Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein. Nature 546:248–253
Acknowledgements
We thank the UVM REACH grant for the support to this research. Computational resources were provided by Anton (PSC, NIH P41GM103712-S1), Stampede (XSEDE, NSF ACI-1053575), and Vermont Advanced Computing Core (VACC).
Author information
Authors and Affiliations
Contributions
J. L. designed the studies and C. L. performed the simulations and analyzed the data. C. L., J. L. and V. M. wrote the paper; all of the authors contributed insights and critical edits to the final manuscript.
Corresponding authors
Ethics declarations
Conflict of Interest
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Liao, C., May, V. & Li, J. PAC1 Receptors: Shapeshifters in Motion. J Mol Neurosci 68, 331–339 (2019). https://doi.org/10.1007/s12031-018-1132-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12031-018-1132-0